Finanzen von Zura Bio Ltd (ZURA)ZURAZura Bio Ltd

Evaluating the bottom line, Zura Bio Ltd maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -72.10%, provide a clear picture of how effectively ZURA converts its operational activities into shareholder value.

In the context of the broader market, ZURA competes directly with industry leaders such as FENC and KYTX. With a market capitalization of $422.61M, it holds a leading position in the sector. When comparing efficiency, ZURA's gross margin of N/A stands against FENC's 95.97% and KYTX's N/A. Such benchmarking helps identify whether Zura Bio Ltd is trading at a premium or discount relative to its financial performance.

Zura Bio has been facing significant financial challenges, with a net loss of $26.3 million in Q2 2026 and a GAAP EPS of -0.21, indicating ongoing profitability issues. However, it has cash reserves of $205.1 million, which can sustain operations until the end of 2028.